Drug major Lupin Ltd has entered into a licensing pact for various patents of cholesterol-lowering drug Antara capsules with US-based Abbott Laboratories and France’s Laboratoires Fournier SA, Lupin said in a statement on Tuesday.
Lupin and its subsidiaries Lupin Pharmaceuticals Inc and Lupin Atlantis Holding SA have entered into a licence agreement with Abbott Laboratories and Laboratoires Fournier SA for various Abbott patents for Antara (Fenofibrate) capsules.
The company did not disclose details of the patent licensing agreement citing confidentiality.
The agreement covers as many as eight patents in the US for the drug besides any divisionals, continuations, continuations in part, reissues, re-examinations, and extensions, the company said.
Shares of Lupin closed up 1.1% at R419.2 on the Bombay Stock Exchange on Tuesday.